Cocrystal Pharma, Inc.

NasdaqCM:COCP Stock Report

Market Cap: US$22.9m

Cocrystal Pharma Management

Management criteria checks 3/4

Cocrystal Pharma's CEO is Sam Lee, appointed in Jan 2008, has a tenure of 16.92 years. total yearly compensation is $627.20K, comprised of 62.9% salary and 37.1% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $126.80K. The average tenure of the management team and the board of directors is 16.9 years and 5.2 years respectively.

Key information

Sam Lee

Chief executive officer

US$627.2k

Total compensation

CEO salary percentage62.9%
CEO tenure16.9yrs
CEO ownership0.6%
Management average tenure16.9yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Oct 18
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14
Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19
We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19
Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06
We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05
We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13
Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Jan 24
What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Cocrystal sees 2021 cash burn of $800k a month

Jan 11

Cocrystal Pharma to test CDI-45205 against coronaviruses

Dec 22

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Dec 20
Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Sam Lee's remuneration changed compared to Cocrystal Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$627kUS$395k

-US$18m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$622kUS$371k

-US$39m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$665kUS$333k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$462kUS$293k

-US$10m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$55m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$241kUS$241k

-US$48m

Sep 30 2019n/an/a

-US$45m

Jun 30 2019n/an/a

-US$45m

Mar 31 2019n/an/a

-US$45m

Dec 31 2018US$412kUS$201k

-US$49m

Sep 30 2018n/an/a

US$435k

Jun 30 2018n/an/a

US$41k

Mar 31 2018n/an/a

US$382k

Dec 31 2017US$253kUS$253k

-US$613k

Compensation vs Market: Sam's total compensation ($USD627.20K) is about average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Sam's compensation has increased whilst the company is unprofitable.

CEO

Sam Lee (64 yo)

16.9yrs

Tenure

US$627,201

Compensation

Dr. Sam Lee, Ph D., Co-founded Cocrystal Pharma, Inc. in 2008 and serves as its President since January 2, 2014 and serves as its Interim Co-Chief Executive Officer since May 2023 and had been its Interim...

Leadership Team

NamePositionTenureCompensationOwnership
Roger Kornberg
Co-Founder4.7yrsUS$184.84k0.53%
$ 121.1k
Sam Lee
Co-Founder16.9yrsUS$627.20k0.55%
$ 126.8k
James Martin
Co-CEO, CFO & Corporate Secretary7.5yrsUS$627.20k0.20%
$ 46.3k

16.9yrs

Average Tenure

64yo

Average Age

Experienced Management: COCP's management team is seasoned and experienced (16.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roger Kornberg
Co-Founder4.7yrsUS$184.84k0.53%
$ 121.1k
Fred Hassan
Independent Director1.7yrsUS$49.47k10.02%
$ 2.3m
Richard Pfenniger
Independent Director3.6yrsUS$44.23k0.072%
$ 16.6k
Phillip Frost
Independent Director10.9yrsUS$84.12k13.23%
$ 3.0m
Steven Rubin
Independent Vice Chairman10.9yrsUS$113.51k0.11%
$ 25.7k
Michael Levitt
Member of Scientific Advisory Boardno datano datano data
Gary Schoolnik
Member of Scientific Advisory Boardno datano datano data
Bob Lehman
Member of Scientific Advisory Boardno datano datano data
Roland Strong
Member of Scientific Advisory Boardno datano datano data
Christophe Verlinde
Member of Scientific Advisory Boardno datano datano data
Anthony Japour
Independent Director5.7yrsUS$79.97k0.073%
$ 16.8k
Baek Kim
Member of Scientific Advisory Boardno datano datano data

5.2yrs

Average Tenure

77yo

Average Age

Experienced Board: COCP's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cocrystal Pharma, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Ahu DemirNOBLE Capital Markets, Inc.
Robert LeBoyerNOBLE Capital Markets, Inc.